Oncolytics Biotech Surges 35% on Promising ASCO Data
By ATTN Desk · Editorial oversight: Sean Han
ONCOLYTICS BIOTECH INC (ONCY): HIGHLIGHTS AS OF 2025-06-11
Stock Performance on June 11, 2025
- Exchange: Nasdaq Capital Market (Ticker: ONCY)
- Closing Price: $0.5795 (up 35.71%)
- Volume: 1,161,582 shares
- 52-Week Range: $0.33 – $1.53
- Market Capitalization: $51.47 million (intraday)
1. Corporate Overview
Oncolytics Biotech Inc. is a clinical-stage biotechnology company headquartered in Calgary, Alberta. Since its founding in 1998, the company has focused on pelareorep (REOLYSIN), an intravenously administered oncolytic virus that:
- Selectively replicates in cancer cells
- Induces direct tumor lysis and both innate and adaptive immune responses
- Can be combined with chemotherapy or immune checkpoint inhibitors
2. Corporate Structure and Experience
- Employee Count: 11–50
- Leadership Team:
- Jared Kelly, Chief Executive Officer (appointed May 2025)
- Christophe Degois, Vice President, Business Development (20+ years in immuno-oncology)
3. Recent Developments and News
-
June 1–5, 2025 (ASCO Annual Meeting)
- GOBLET Phase I/II trial in pancreatic ductal adenocarcinoma (PDAC) demonstrated:
- Overall Response Rate: 62%
- Disease Control Rate: 85%
- 12-Month Survival Rate: 45%
- Evidence of T-cell expansion and increased cytokine/chemokine levels
- GOBLET Phase I/II trial in pancreatic ductal adenocarcinoma (PDAC) demonstrated:
-
February 14, 2025
- Received a Nasdaq notification for minimum bid price deficiency (closing below $1 for 30 consecutive business days)
- Must regain compliance by August 12, 2025
-
June 11, 2025
- Filed a Form 6-K with the SEC; attached press release provided corporate updates but did not include detailed financial statements
4. Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Market Cap (intraday) | $51.47 million |
| Total Cash (MRQ) | $15.3 million |
| Total Debt/Equity (MRQ) | 15.40% |
| Net Loss (TTM) | –$31.5 million |
| Diluted EPS (TTM) | –$0.28 |
| 1-Year Target Estimate (Yahoo) | $4.09 |
- Pipeline Focus: Late-stage trials in metastatic breast cancer and PDAC, both with FDA Fast Track designation
- Collaborations: Partnerships with Roche, Pfizer, Merck Serono, and academic institutions including the Mayo Clinic and Duke University
- Intellectual Property: Holds over 415 patents worldwide
5. Market Position and Industry Context
- Sector: Immuno-oncology, competing with checkpoint inhibitors and cell therapies
- Differentiator: Systemic delivery of pelareorep in comparison to intratumoral injections
- Indications in Development: HR+/HER2– breast cancer; gastrointestinal and hematologic malignancies
- Strategic Goal: Seek regulatory approval in indications with high unmet needs and potential commercial opportunities
TL;DR
- June 11, 2025: ONCY shares increased 35.71% to $0.5795 following ASCO data indicating a 62% overall response rate in PDAC.
- February 14, 2025: Nasdaq notified the company of a bid-price deficiency; compliance deadline is August 12, 2025.
- Financials: $15.3 million cash; –$31.5 million net loss over trailing twelve months; no positive EPS reported.
- Catalysts: Focus on FDA submissions in metastatic breast and pancreatic cancer; earnings announcement expected between July 30–August 4, 2025; Nasdaq bid-price compliance monitoring.